Dignify Therapeutics Receives NIH Grants for Groundbreaking Research
Dignify Therapeutics, a leader in developing treatments for bladder and bowel issues, is thrilled to share that it has secured two important research grants from the National Institutes of Health. These funds represent a significant step forward in the company's dedication to enhancing therapeutic options for those facing these challenging health conditions.
The Importance of the NIH Grants
These new grants add to a noteworthy previous funding amount of $20 million, signaling the NIH's acknowledgment of the pressing demand for effective therapies. The specific grants awarded include R43DK138600 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and R43AG088838 from the National Institute on Aging (NIA). With this new influx of resources, Dignify is poised to expand its research and development efforts.
Expert Views on the Necessity for Research
Dr. Karl B. Thor, the Chief Scientific Officer at Dignify, expressed his gratitude, saying, "We are incredibly thankful for the support from multiple NIH Institutes. The urgent need for therapies that help restore control over bladder and bowel functions cannot be overstated, particularly for elderly individuals and those affected by neurological conditions such as spinal injuries and multiple sclerosis." His remarks underscore how bladder and bowel dysfunction issues often go unnoticed, yet they profoundly impact both patients and their caregivers.
Targeting Unmet Medical Needs
The grants will enable Dignify to expand its work on innovative drug therapies aimed at tackling urinary and fecal incontinence. Dr. Qiaojuan Zhang, a principal investigator at Duke University’s Department of Neurology, will spearhead the project supported by the NIA, emphasizing the essential need for solutions that provide on-demand voiding options for older adults and disabled individuals.
Understanding the Research's Impact
Many family caregivers know that bladder and bowel dysfunction are among the leading causes of institutionalization for older adults. This issue highlights the necessity of developing therapeutic options that not only enhance quality of life but also lessen the strain on caregivers. Dr. Thor stressed that these therapies are crucial not just for physical well-being but also for fostering dignity within social contexts for those affected.
About Dignify Therapeutics
Dignify Therapeutics was founded by a team of accomplished entrepreneurs and scientists committed to creating safe and effective pharmaceutical treatments for bladder and bowel dysfunction. The company enjoys backing from respected organizations, including RA Capital Management and the North Carolina Biotechnology Center, along with support from government bodies. Based in the First Flight Venture Center, Dignify is steadfast in its mission to meet the needs of this overlooked population and foster innovation in therapeutic development.
Frequently Asked Questions
What are the main areas of focus for Dignify Therapeutics?
Dignify Therapeutics concentrates on developing therapies for bladder and bowel dysfunction, specifically aiming to offer innovative drug treatments for incontinence.
How much total funding has Dignify received from the NIH?
Dignify Therapeutics has received notable research grants from the NIH, which add to their prior funding of $20 million to support their therapeutic initiatives.
Who is in charge of the new research backed by the NIA?
Dr. Qiaojuan Zhang from Duke University’s Department of Neurology will lead the NIA-sponsored research project.
Why is it crucial to research bladder and bowel dysfunction?
This research is essential because bladder and bowel dysfunction can significantly impact the elderly and those with neurological conditions, ultimately improving their overall quality of life.
Where is Dignify Therapeutics located?
Dignify Therapeutics operates from the First Flight Venture Center in Research Triangle Park, North Carolina.
